Multiple Myeloma CAR-T Treatment Strategy:From Preparation TO Management,One Can Understand!
Multiple Myeloma CAR-T Treatment Strategy:From Preparation TO Management,One Can Understand!
Would you like to understand the entire process of CAR-T cell infusion? This comprehensive guide covers everything from pre-infusion preparation to infusion precautions and post-infusion management, ensuring you have a clear understanding and no longer feel lost! Read on!
Multiple myeloma car-t treatment process
CAR-T cell infusion, as a cutting-edge therapeutic approach, has shown remarkable efficacy. However, it also requires meticulous preparation and close monitoring. In the following sections, we will detail the preparations before infusion, precautions during infusion, and management after infusion, providing you with a comprehensive understanding of the entire process.
I. Preparation Before CAR-T Cell Infusion
Infection Screening and Prevention: Prior to CAR-T cell infusion, doctors will screen patients for active infections to ensure safety. Additionally, a series of preventive measures will be taken to minimize the risk of infection.
Central Nervous System(CNS) Evaluation: If a patient has a history of CNS diseases or complications, doctors will pay particular attention and may postpone the infusion to ensure the patient’s safety.
Prophylactic Medications: To prevent neurological adverse events such as seizures, doctors may recommend that patients take medications like levetiracetam orally.
II. Precautions During CAR-T Cell Infusion
Infusion Timing: CAR-T cell infusion typically occurs within 1-2 days after the completion of preconditioning chemotherapy, but no later than 7 days. Doctors will determine the optimal infusion timing based on the patient’s specific condition.
Infusion Dose: The dose of CAR-T cells is closely related to therapeutic efficacy and potential toxicities. The recommended infusion doses may vary significantly among different products, and doctors will determine the appropriate dose based on the pre-clinical data for each product.
Vital Signs Monitoring: Prior to CAR-T cell infusion, doctors will initiate vital sign monitoring, including blood pressure, heart rate, respiratory rate, and others, to ensure patient safety.
III. Management After CAR-T Cell Infusion
Continuous Monitoring: After infusion, doctors will continuously monitor the patient’s vital signs until the symptoms of cytokine release syndrome (CRS), a common side effect, have resolved. CRS is typically manageable through medication and close monitoring.
Inpatient Observation: To ensure patient safety, doctors will recommend inpatient observation for at least 7-14 days after infusion, during which time they will perform daily physical examinations and monitor complete blood counts, biochemistry, coagulation function, arterial blood gas analysis, and serum markers such as C-reactive protein, ferritin, interleukin-6, and others.
CRS Management: If CRS occurs, doctors will promptly initiate appropriate treatment measures, including medication and close monitoring, to ensure patient safety. They will also adjust the treatment plan based on the severity of CRS and the patient’s overall condition.
In summary, while CAR-T cell infusion represents a cutting-edge therapeutic approach, with adequate preparation and rigorous monitoring, its safety and efficacy can be ensured. We hope this comprehensive guide has provided you with a better understanding of the CAR-T cell infusion process and precautions, serving as a valuable reference for your treatment journey.